Project Grant R21AI182808
Award Date
7/3/25
Completion Date
6/30/27
Dollars Obligated
$416K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $721,194 to Florida State University to conduct research on the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: (1) investigate the structural and functional roles of the FtsQ-FtsZ protein interaction; (2) characterize the structure,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award of $2,248,740.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research by Michigan State University to develop new nitro-containing compounds to treat mycobacterial infections, including tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The key products and services to be delivered include: Optimizing a series of novel nitrofuran compounds, such as the parent...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $130,776 to Lake Forest College to characterize the role of the mycobacterial BrkB ortholog in the pathogenesis of tuberculosis (TB). The project aims to identify the biochemical function and substrates of the BrkB protein, determine its mechanism for requiring extracellular growth, and measure its role under...
This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Yale University to understand antibiotic tolerance in Mycobacterium tuberculosis (MTB). The key objectives are to: 1) Identify the subcellular environments and carbon sources associated with drug-tolerant MTB, and 2) Develop in vitro culture conditions mimicking these environments for future...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support research to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The $820,246 award to the Albert Einstein College of Medicine will be used to investigate the roles of these secreted proteins in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...